At a glance
Nirsevimab Coverage, Children 0 to 7 months
Nirsevimab coverage for children 0 to 7 months is assessed through U.S. jurisdictions' Immunization Information Systems Resources (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group.
Nirsevimab coverage estimate numerators include the number of children who received at least one dose of nirsevimab from April 1, 2024, through the end of the reporting month, based on information that state, territorial, and local public health agencies report to CDC. Some jurisdictions may report data submitted by tribes; however, CDC is unable to report estimates by tribe. Estimates include children who are deceased but received nirsevimab during the current season. Children receiving doses are attributed to the jurisdiction in which the child resides unless noted otherwise. Quality and completeness of data may vary across jurisdictions. Nirsevimab coverage denominators are obtained from 2020 U.S. Census Bureau population estimates. Population denominators estimate the number of children born since April 1, 2024, and are adjusted monthly to allow aging in for infants born each month.
Monthly estimates shown are cumulative, reflecting all children who received nirsevimab from April 2024 through the end of the reporting month. Cumulative estimates include any historical data reported since the previous submission. National estimates are not presented since not all U.S. jurisdictions are currently reporting their IIS data to CDC. Jurisdictions reporting data to CDC include U.S. states, some localities, and territories.
Because IIS data are intended to capture all doses administered within a jurisdiction rather than a sample, standard errors are not calculated.
Laws and policies regarding the submission of vaccination data to an IIS vary by state, which may impact the completeness of vaccination coverage reflected for a jurisdiction.
Coverage estimates based on IIS data are expected to differ from National Immunization Survey (NIS) estimates for children. NIS estimates are based on a sample that may not be representative after survey weighting and vaccination status is determined by survey respondent rather than vaccine records or administrations. Quality and completeness of IIS data may vary across jurisdictions. In general, NIS estimates tend to overestimate coverage due to overreporting and IIS estimates may underestimate coverage due to incompleteness of data in certain jurisdictions.
IIS coverage estimates reported on jurisdictions' dashboards may use different criteria for numerators and denominators (e.g. jurisdictions may use IIS-based denominator instead of census population) and thus IIS estimates may differ from those reported on CDC's Weekly RSV Vaccination dashboard.
- Figure 6A. Monthly Cumulative Number and Percent of Children <8 Months Who Received Nirsevimab*,† by Jurisdiction, United States. Data Source: U.S. Jurisdiction Immunization Information Systems (IIS).
- Figure 6B. Monthly Cumulative Number and Percent of Children <8 Months Who Received Nirsevimab*,† by Jurisdiction, United States. Data Source: U.S. Jurisdiction Immunization Information Systems (IIS).
Download Data for Figures 6A & 6B
*Some jurisdictions' data are not displayed if they were not available by data retrieval timelines. Data displayed include both valid and invalid doses, persons with last known addresses in the jurisdiction, and persons with unknown addresses within the jurisdiction. Data excludes people whom a provider has indicated have left the jurisdiction. Number of doses administered, and coverage estimates for a given month may change over time for some jurisdictions. New York City (New York) and Philadelphia (Pennsylvania) report data separately from their respective states. New York state data exclude New York City and Pennsylvania state data exclude Philadelphia County. Chicago is a funded jurisdiction; however, their data are reported with Illinois due to lack of a comparable denominator to calculate coverage.
†Figure 6A (line graph) will not display any lines for jurisdictions whose data have not been submitted to CDC; these jurisdictions appear gray in the Figures 6B. Some jurisdictions' vaccination programs may be aligned to regional virus circulation patterns (e.g., some Pacific Islands may administer nirsevimab on a different schedule than the continental U.S.).